Trial Profile
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenabasum (Primary)
- Indications Systemic scleroderma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Corbus Pharmaceuticals
- 25 Mar 2021 Status changed from active, no longer recruiting to discontinued.
- 29 Jun 2020 According to an Corbus Pharmaceuticals media release, data from this study will be data will be presented in a recorded oral presentation and two e-posters at the 6th Systemic Sclerosis World E-Congress on June 29, 2020.
- 29 Jun 2020 Results published in the Corbus Pharmaceuticals Media Release.